SynthesisJournal of thrombosis and thrombolysis2026
Safety and efficacy of Cangrelor versus GPIIb/IIIa inhibitors as adjunctive therapy in endovascular treatment of acute ischemic stroke: a systematic review and meta-analysis.
Synthesis in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endovascular treatment (EVT) plays a critical role in the management of acute ischemic stroke (AIS). To enhance reperfusion outcomes, intravenous antiplatelet agents such as glycoprotein IIb/IIIa inhibitors (GPIs) are commonly administered during EVT. cangrelor, a fast-acting, reversible P2Y12 inhibitor, has emerged as a potential alternative due to its rapid onset and offset of action. However, comparative data on its efficacy and safety relative to GPIs in this context are limited. This study aimed to systematically evaluate the efficacy and safety of cangrelor versus GPIs as adjunctive antiplatelet therapies during EVT in AIS patients. We conducted a systematic review and meta-analysis following PRISMA guidelines, with protocol registration on PROSPERO (CRD420251047232). A comprehensive literature search was performed in PubMed, Scopus, and Web of Science, through May 4, 2025. Studies comparing cangrelor and GPIs during EVT in AIS were included. Data on procedural success, intracranial hemorrhage, and mortality were extracted and analyzed using Review Manager 5.4. Five studies including 616 participants (cangrelor: 318, GPIs: 298) were included. No significant difference was observed between groups in achieving the modified treatment in cerebral infarction (mTICI) score ≥ 2b (RR = 1.04, 95% CI [1.00–1.09], P = 0.07), mTICI ≥ 2c (RR = 1.19 (95% CI [0.87, 1.61], P = 0.27), or mTICI ≥ 3 (RR = 1.07 (95% CI [0.81 to 1.42], p = 0.62). Safety outcomes, including symptomatic intracranial hemorrhage and mortality, were comparable. Despite limited data, current evidence indicates that cangrelor may serve as a viable alternative to GPIs in the EVT of AIS, with comparable efficacy and safety profiles. However, definitive conclusions require validation through well-designed prospective randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.